Global Sisomicin Sulfate (CAS 531702) Market is expected to grow at a CAGR of XX% during the forecast period. The major factors driving the growth of this market are increasing prevalence of bacterial infections, rising geriatric population, and increasing number of hospital-acquired infections. The global sisomicin sulfate market is segmented on the basis of type, application and region. On the basis of type, it is classified into 99% purity type and 95% purity type. On the basis of application, it is classified into intramuscular injection and intravenous drip. On the basis of region, it is classified into North America, Latin America, Europe, Asia Pacific and Middle East & Africa regions. 5a) Sisomicin sulfate was first isolated in 1957 by scientists at Eli Lilly & Company (then called Elanco). They were looking for new antibiotics with activity against gram-positive bacteria such as Streptococcus pneumoniae (pneumonia), Staphylococcus aureus (staph infection), Streptococcus pyogenes (strep throat) and Enterococcus faecalis (urinary tract infection). 5b) In 1958 they found sisomicin sulfate which had good activity against these bacteria but also had some activity against gram-negative bacteria such as Escherichia coli, Salmonella typhi, Klebsiella pneumoniae and Proteus vulgaris.
- Sisomicin sulfate is a potent antibiotic that is used to treat bacterial infections.
- The drug has been approved for use in the United States since 1985 and is marketed by Eli Lilly and Company under the trade name Tetracycline HCl.
- It has been shown to be effective against a wide range of bacteria, including those that are resistant to other antibiotics such as penicillin, erythromycin, tetracycline, chloramphenicol and ampicillin.
- The drug can be administered orally or intravenously and it is not absorbed from the gastrointestinal tract so it does not have any side effects on the stomach or intestines like other antibiotics do which makes it an attractive option for patients who cannot tolerate other drugs because of their gastrointestinal side effects.
Industry Growth Insights published a new data on “Sisomicin Sulfate (CAS 53179-09-2) Market”. The research report is titled “Sisomicin Sulfate (CAS 53179-09-2) Market research by Types (99% Purity Type, 95% Purity Type, Others), By Applications (Intramuscular Injection, Intravenous Drip), By Players/Companies Pengyao Pharm, Tianjin Pharm, Pude Pharm, Xierkang Pharm, Taintaishan Pharm, Qiangsheng Pharm, Samjin Pharm, Fulford (India), Gentle Pharm”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sisomicin Sulfate (CAS 53179-09-2) Market Research Report
By Type
99% Purity Type, 95% Purity Type, Others
By Application
Intramuscular Injection, Intravenous Drip
By Companies
Pengyao Pharm, Tianjin Pharm, Pude Pharm, Xierkang Pharm, Taintaishan Pharm, Qiangsheng Pharm, Samjin Pharm, Fulford (India), Gentle Pharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Sisomicin Sulfate (CAS 53179-09-2) Market Report Segments:
The global Sisomicin Sulfate (CAS 53179-09-2) market is segmented on the basis of:
Types
99% Purity Type, 95% Purity Type, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Intramuscular Injection, Intravenous Drip
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pengyao Pharm
- Tianjin Pharm
- Pude Pharm
- Xierkang Pharm
- Taintaishan Pharm
- Qiangsheng Pharm
- Samjin Pharm
- Fulford (India)
- Gentle Pharm
Highlights of The Sisomicin Sulfate (CAS 53179-09-2) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 99% Purity Type
- 95% Purity Type
- Others
- By Application:
- Intramuscular Injection
- Intravenous Drip
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sisomicin Sulfate (CAS 53179-09-2) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sisomicin sulfate is a sulfated derivative of the antibiotic sisomicin. It is used in the treatment of infections caused by bacteria, such as pneumonia, bronchitis, and urinary tract infections.
Some of the key players operating in the sisomicin sulfate (cas 53179-09-2) market are Pengyao Pharm, Tianjin Pharm, Pude Pharm, Xierkang Pharm, Taintaishan Pharm, Qiangsheng Pharm, Samjin Pharm, Fulford (India), Gentle Pharm.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sisomicin Sulfate (CAS 53179-09-2) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sisomicin Sulfate (CAS 53179-09-2) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sisomicin Sulfate (CAS 53179-09-2) Market - Supply Chain
4.5. Global Sisomicin Sulfate (CAS 53179-09-2) Market Forecast
4.5.1. Sisomicin Sulfate (CAS 53179-09-2) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sisomicin Sulfate (CAS 53179-09-2) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sisomicin Sulfate (CAS 53179-09-2) Market Absolute $ Opportunity
5. Global Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Type
5.3.1. 99% Purity Type
5.3.2. 95% Purity Type
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Application
6.3.1. Intramuscular Injection
6.3.2. Intravenous Drip
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sisomicin Sulfate (CAS 53179-09-2) Demand Share Forecast, 2019-2026
9. North America Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Application
9.4.1. Intramuscular Injection
9.4.2. Intravenous Drip
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Type
9.7.1. 99% Purity Type
9.7.2. 95% Purity Type
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sisomicin Sulfate (CAS 53179-09-2) Demand Share Forecast, 2019-2026
10. Latin America Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Application
10.4.1. Intramuscular Injection
10.4.2. Intravenous Drip
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Type
10.7.1. 99% Purity Type
10.7.2. 95% Purity Type
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sisomicin Sulfate (CAS 53179-09-2) Demand Share Forecast, 2019-2026
11. Europe Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Application
11.4.1. Intramuscular Injection
11.4.2. Intravenous Drip
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Type
11.7.1. 99% Purity Type
11.7.2. 95% Purity Type
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sisomicin Sulfate (CAS 53179-09-2) Demand Share, 2019-2026
12. Asia Pacific Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Application
12.4.1. Intramuscular Injection
12.4.2. Intravenous Drip
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Type
12.7.1. 99% Purity Type
12.7.2. 95% Purity Type
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sisomicin Sulfate (CAS 53179-09-2) Demand Share, 2019-2026
13. Middle East & Africa Sisomicin Sulfate (CAS 53179-09-2) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Application
13.4.1. Intramuscular Injection
13.4.2. Intravenous Drip
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sisomicin Sulfate (CAS 53179-09-2) Market Size and Volume Forecast by Type
13.7.1. 99% Purity Type
13.7.2. 95% Purity Type
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sisomicin Sulfate (CAS 53179-09-2) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sisomicin Sulfate (CAS 53179-09-2) Market: Market Share Analysis
14.2. Sisomicin Sulfate (CAS 53179-09-2) Distributors and Customers
14.3. Sisomicin Sulfate (CAS 53179-09-2) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pengyao Pharm
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Tianjin Pharm
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pude Pharm
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Xierkang Pharm
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Taintaishan Pharm
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Qiangsheng Pharm
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Samjin Pharm
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Fulford (India)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Gentle Pharm
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook